Why the study?
Does terazosin reduce blood pressure across 24 hours in hypertensive patients compared to placebo?
Does terazosin reduce blood pressure across 24 hours in hypertensive patients compared to placebo?
Answers are grounded in this paper and cite their sources.
24-hour noninvasive blood pressure monitoring demonstrates that long-term terazosin therapy significantly lowers blood pressure throughout the day and night in hypertensive patients.
Noninvasive BP monitoring was performed in hypertensive patients before and during placebo therapy and before and during therapy with the long-acting peripheral alpha-adrenergic receptor antagonist, terazosin hydrochloride. Placebo therapy did not result in significant changes in casual BP or in averages of whole-day, daytime, or nighttime BPs. Short-term therapy with terazosin did not induce significant changes in casual supine or daytime BPs. However, whole-day BP monitoring disclosed that nighttime BPs were lower during shortterm therapy. Moreover, the circadian pattern of BP was shifted downward during terazosin therapy. Long-term therapy with terazosin resulted in significant changes in BP. All BP values were lowered significantly. The differences in the circadian BP pattern between placebo and long-term terazosin therapy show that in these patients BP was lowered throughout the 24 hours of the day. The results of the study emphasize the usefulness of 24-hour BP monitoring in the evaluation of the effectiveness of long-acting antihypertensive agents.
No takes yet. Share an insight, caveat, or question.
Jan I.M. Drayer (1983) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: